Abstract
In the ubiquitylation system, E3 ubiquitin ligases play a key role in determining substrate specificity and catalyzing the transfer of ubiquitin from E2 enzymes to the substrate. Growing evidence has shown that E3 ubiquitin ligases are involved in cancer development and progression. The RING-type and HECT-type E3 ligases are the classically categorized groups of E3 ubiquitin ligases, and more of these enzymes are being shown to be potential targets for cancer therapy. The recently classified RBR E3 ligases catalyze the transfer of ubiquitin by a RING/HECT hybrid-like mechanism. Notably, these ligases are also emphasized as important potential candidates for targets of cancer treatment drugs. The present review provides an overview of the RING-, HECT- and RBR-type E3 ligases, and discusses their roles in cancer and cancer therapy.
Current Cancer Drug Targets
Title:RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer
Volume: 16 Issue: 2
Author(s): Chiharu Uchida and Masatoshi Kitagawa
Affiliation:
Keywords: Cancer, HECT, E3, RBR, RING, ubiquitin.
Abstract: In the ubiquitylation system, E3 ubiquitin ligases play a key role in determining substrate specificity and catalyzing the transfer of ubiquitin from E2 enzymes to the substrate. Growing evidence has shown that E3 ubiquitin ligases are involved in cancer development and progression. The RING-type and HECT-type E3 ligases are the classically categorized groups of E3 ubiquitin ligases, and more of these enzymes are being shown to be potential targets for cancer therapy. The recently classified RBR E3 ligases catalyze the transfer of ubiquitin by a RING/HECT hybrid-like mechanism. Notably, these ligases are also emphasized as important potential candidates for targets of cancer treatment drugs. The present review provides an overview of the RING-, HECT- and RBR-type E3 ligases, and discusses their roles in cancer and cancer therapy.
Export Options
About this article
Cite this article as:
Uchida Chiharu and Kitagawa Masatoshi, RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer, Current Cancer Drug Targets 2016; 16 (2) . https://dx.doi.org/10.2174/1568009616666151112122801
DOI https://dx.doi.org/10.2174/1568009616666151112122801 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Exploring the Mitochondrial Apoptotic Cell Death Landscape and Associated Components Serving as Molecular Targets, Primarily for Synthetic and Natural Drugs Targeting Oncology Therapeutics
Current Molecular Pharmacology A Review on Colorimetric Sensing of Tumor Markers Based on Enzyme-Mimicking Nanomaterials
Current Medicinal Chemistry Carrier Deformability in Drug Delivery
Current Pharmaceutical Design Mouse and Human Embryonic Stem Cells: Can They Improve Human Health by Preventing Disease?
Current Topics in Medicinal Chemistry Nanocarriers Based Anticancer Drugs: Current Scenario and Future Perceptions
Current Drug Targets Clinical Use of Therapies Targeting Tumor Vasculature and Stroma
Current Cancer Drug Targets Renaissance of the Biologically Active Vitamin A Derivatives: Established and Novel Directed Therapies for Cancer and Chemoprevention
Current Pharmaceutical Design Endoglin-Targeted Cancer Therapy
Current Drug Delivery Bisphosphonates: Molecular Mechanisms of Action and Effects on Bone Cells, Monocytes and Macrophages
Current Pharmaceutical Design Development of Highly Efficient KinExA Immunosensor-Based Assay for the Measurement of Carcinoembryonic Antigen in Serum
Current Analytical Chemistry Synthesis and Antiproliferative Evaluation of Hybrids of Indolin-2-one and Quinazoline-4(3H)-one Linked via Imine Bond
Letters in Drug Design & Discovery Should the Status of the Pathway Mediated by BRCA1 and BRCA2 be Evaluated Before Selecting Cancer Chemotherapy Drugs?
Current Pharmacogenomics Multifunctional Nanoparticles, Nanocages and Degradable Polymers as a Potential Novel Generation of Non-Invasive Molecular and Cellular Imaging Systems
Recent Patents on Nanotechnology Matrix Metalloproteinases as Valid Clinical Target
Current Pharmaceutical Design Prothymosin α and its C-Terminal Immunoreactive Decapeptide Show No Evidence of Acute Toxicity: A Preliminary <i>In Silico</i>, <i>In Vitro</i> and <i>In Vivo</i> Investigation
Current Medicinal Chemistry 2,3-Dichloro-1,4-Naphthoquinone in Organic Synthesis: Recent Advances
Mini-Reviews in Organic Chemistry Novel Compounds from Marine Microorganisms that Inhibit Mammalian DNA Polymerase
Current Organic Chemistry p53-Induced Apoptosis and Inhibitors of p53
Current Medicinal Chemistry Tumor Growth-Promoting Properties of Macrophage Migration Inhibitory Factor
Current Pharmaceutical Design Exploiting HPV-Induced Carcinogenesis for a Rational Drug Development in Cervical Cancer
Current Cancer Drug Targets